Conference details: 20th & 21st May 2013, Copthorne Tara Hotel, London, UK
Examine practical issues within the industry and network with leading experts at SMi’s Pain Therapeutics conference
SMi’s Pain Therapeutics conference returns to London on the 20th & 21st May 2013 with a two day intensive agenda highlighting the latest developments in pain therapeutics and offering attendees a unique platform to engage with key opinion leaders and esteemed academia to learn the challenges and successes in this field. Pain is the primary reason that patients seek medical care and the pain therapeutics industry is currently under financial strain. With this in mind, the conference will highlight improvements in R&D methods and certifying that drugs being put forward for clinical trials are given the best chance to succeed. Key factors include recent findings in areas such as: current targets for analgesic development, personalised medicine, the cannabinoid approach, imaging modalities, experimental models in early phase clinical development and improving clinical trial success rates.
SMi are pleased to introduce Narender Gavva, Scientific Director, Amgen, who will give a presentation on greater emphasis on preclinical discovery, outlining potential false-positive hotspots and the best practices for target selection criteria. The conference will also present a Pfizer Session on current considerations in sodium channel blockers for pain management, lead by Richard Butt, Director, Research Project Leader, Pfizer. This session will highlight discovery and preclinical development of selective sodium channel blockers as well as subtype selective sodium channel blockers.
Visit www.pain-therapeutics.co.uk for the full speaker line-up, which includes presentations from: Amgen; Eli Lilly; Convergence Pharmaceuticals; Benitec Biopharma; Nektar Therapeutics and MedImmune.
Delegates can also choose between two half day workshops, both held on 22nd May: Workshop A is on: Human Pain Models – Lost in Translation? Led by Jonathan Stewart, Consultant, Pain Medicine, Imperial NHS Trust, London, Zahid Ali, Senior Director, Pfizer and Remigiusz Lecybyl, Consultant in Chronic Pain, Lewisham Hospital.
Workshop B is on: Using phenotyping and imaging to improve early drug development and clinical trial design, led by Anthony Jones, Professor of Neuro-rheumatology, University of Manchester.
ACNR readers can claim a discount of £300 so make sure you quote ACNR when enquiring.